The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users

Mahmodreza Miri-Bonjar; Alireza Khorram; Alireza Ansari-Moghaddam

doi:10.5812/jhealthscope.55868

The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users

authors:

Mahmodreza Miri-Bonjar ¹ , avatar Alireza Khorram ^{1
, *} , Alireza Ansari-Moghaddam ¹

1 Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran

Health Scope: Vol.5, issue 1; e32754

published online: February 15, 2016

article type: Editorial

received: August 28, 2015

accepted: September 22, 2015

DOI: https://doi.org/10.5812/jhealthscope.55868

how to cite: Miri-Bonjar M, Khorram A, Ansari-Moghaddam A. The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users. Health Scope. 2016;5(1):e32754. https://doi.org/10.5812/jhealthscope.55868.

Keywords

Harm Reduction Drug Users HIV Hepatitis C Blood-Borne Pathogens

References

1.
Saigi N, Espelt A, Folch C, Sarasa-Renedo A, Castellano Y, Majo X, et al. Differences in illegal drug consumption between native and immigrants in a large sample of injected drug users in Catalonia (Spain). Adicciones. 2014;26(1):69-76. [PubMed ID: 24652401].
2.
Palmateer NE, Taylor A, Goldberg DJ, Munro A, Aitken C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One. 2014;9(8). eee104515. [PubMed ID: 25110927]. https://doi.org/10.1371/journal.pone.0104515.
3.
Philbin MM, FuJie Z. Exploring stakeholder perceptions of facilitators and barriers to using needle exchange programs in Yunnan Province, China. PLoS One. 2014;9(2). eee86873. [PubMed ID: 24498286]. https://doi.org/10.1371/journal.pone.0086873.
4.
Huang YF, Yang JY, Nelson KE, Kuo HS, Lew-Ting CY, Yang CH, et al. Changes in HIV incidence among people who inject drugs in Taiwan following introduction of a harm reduction program: a study of two cohorts. PLoS Med. 2014;11(4). eee1001625. [PubMed ID: 24714449]. https://doi.org/10.1371/journal.pmed.1001625.
5.
Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med. 2014;11(6). eee1001663. [PubMed ID: 24937136]. https://doi.org/10.1371/journal.pmed.1001663.
6.
Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. Aids. 2008;22 Suppl 2:S81-92. [PubMed ID: 18641473]. https://doi.org/10.1097/01.aids.0000327439.20914.33.
7.
Edmonton AB. Working with people who use drugs: A harm reduction approach. Non Prescription Needle Use Initiativ. Edmonton: Canadian Liver Foundation; 2007. Available from: http://www.liver.ca/files/PDF/Publications_English/Working_with_People_who_Use_Drugs-A_Harm_Reduction_Approach_Manual_and_all_supplements.pdf.
8.
Barbeau A, Breton G, Lemieux B, Butterworth RF. Bilirubin metabolism - preliminary investigation. Can J Neurol Sci. 1976;3(4):365-72. [PubMed ID: 1000423].
9.
Thomson N. Harm reduction history, response, and current trends in Asia. J Food Drug Anal. 2013;21(4):S113-6. [PubMed ID: 25264414]. https://doi.org/10.1016/j.jfda.2013.09.047.

comments